E.W. "Al" Thrasher
Status: Funded - Open
Efficacy and safety of moxidectin plus albendazole, moxidectin plus tribendimidine, albendazole plus oxantel pamoate and moxidectin alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a randomized controlled trial
Jennifer Keiser, PhD
BACKGROUND: Between 600 and 800 million people are infected with one or several of the common soil-transmitted helminths (STH) that are Ascaris lumbricoides, Trichuris trichiura, and hookworm. Infection is typically most intense and debilitating in school-aged children.
GAP: Albendazole and mebendazole are used at large scale to treat and control infections with STH, however these drugs are not effective against T. trichiura and drug resistance is a threat. We aim to test new drug combinations using moxidectin (a drug used for decades in veterinary medicine, currently in Phase 3 trials for the treatment of onchocerciasis) to increase efficacy against T. trichiura infection and possibly delay resistance.
HYPOTHESIS: We hypothesize that moxidectin has a high efficacy against T. trichiura infections and in combination with albendazole or tribendimidine a broad efficacy spectrum against the three STH infections.
METHODS: 600 children will be enrolled in the trial and will be randomized to four treatment arms: moxidectin plus albendazole, moxidectin plus tribendimidine, moxidectin and albendazole plus oxantel pamoate. The Kato-Katz and PCR techniques will be used for the quantitative assessment of STH both at baseline and follow-up in order to calculate cure and egg reduction rates against T. trichiura and concomitant STH infections.
IMPACT: The outcomes of this study will aid to combat T. trichiura infections with more effective tools and to help to make the neglected poor populations in endemic countries free of these debilitating diseases that sustain the vicious cycle of poverty and ill-health.
Swiss Tropical & Public Health Institute